CLYM Climb Bio, Inc.
Price Chart
Executive Summary
Cindy Driscoll, Senior Vice President, Finance and principal accounting officer at Climb Bio, will depart the company effective April 30, 2026, following a mutual separation agreement. Her responsibilities will be assumed by CFO Dr. Susan Altschuller, who will now serve as principal accounting officer in addition to her current role.
Actionable Insight
Monitor for any subsequent filings regarding new finance leadership hires or changes in financial reporting accuracy; the consolidation of CFO and principal accounting officer roles may increase execution risk in financial oversight near-term.
Key Facts
- Cindy Driscoll is departing as Senior Vice President, Finance and principal accounting officer effective April 30, 2026
- The separation was mutually agreed upon
- Dr. Susan Altschuller, current CFO, will assume the role of principal accounting officer
- No changes to Dr. Altschuller's compensation were made in connection with the appointment
- Dr. Altschuller has extensive financial leadership experience at biotech firms including Cerevel Therapeutics, ImmunoGen, and Alexion Pharmaceuticals
Financial Impact
No immediate financial impact disclosed; no compensation changes for CFO
Risk Factors
- Increased workload for CFO could impact financial reporting quality
- Potential for additional departures if part of broader restructuring
- Governance risk from concentration of financial leadership roles
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-142114 |
| Document: 0001193125-26-142114-index-headers.html | 0001193125-26-142114 |
| Document: 0001193125-26-142114-index.html | 0001193125-26-142114 |
| Document: 0001193125-26-142114.txt | 0001193125-26-142114 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
today
|
8-K
| $11.44 awaiting T+5 | awaiting T+5 | — | $11.44 (+0.00%) |
|
Jun 12, 2026
today
|
424B5
| $11.44 awaiting T+5 | awaiting T+5 | — | $11.44 (+0.00%) |
|
Jun 10, 2026
3d ago
|
EFFECT
| $11.14 awaiting T+5 | awaiting T+5 | — | $11.44 (+2.69%) |
|
Jun 5, 2026
8d ago
|
8-K
| $10.77 awaiting T+5 | awaiting T+5 | — | $11.44 (+6.22%) |
|
May 29, 2026
14d ago
|
S-3
| $11.80 $10.55 | ▼ −10.59% | ▼ −7.84% | $11.44 (−3.05%) |
|
May 7, 2026
5w ago
|
8-K
| $11.91 $11.41 | ▼ −4.20% | ▼ −5.70% | $11.44 (−3.95%) |
|
May 5, 2026
5w ago
|
8-K
| $11.45 $11.17 | ▼ −2.45% | ▼ −4.43% | $11.44 (−0.09%) |
|
Apr 28, 2026
6w ago
|
8-K
| $9.26 $9.69 | ▼ −4.64% | ▼ −2.95% | $11.44 (−23.54%) |
|
Apr 24, 2026
7w ago
|
DEFA14A
| $9.50 $9.69 | ▲ +2.00% | ▲ +1.60% | $11.44 (+20.42%) |
|
Apr 3, 2026
10w ago
|
8-K
| $6.74 $8.63 | ▲ +28.04% | ▲ +23.91% | $11.44 (+69.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access